DDInter948 DDInter1125
Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007.
Maraviroc {u} (Compound) binds {v} (Gene) CYP3A4
Maraviroc {u} (Compound) upregulates {v} (Gene) CNPY3
Maraviroc {u} (Compound) is included by {v} (Pharmacologic Class) Chemokine Co-receptor 5 Antagonists
Maraviroc {u} (Compound) downregulates {v} (Gene) NPDC1
Maraviroc {u} (Compound) causes {v} (Side Effect) Herpes virus infection
Maraviroc {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Minoxidil
Maraviroc {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Maraviroc {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Maraviroc {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Maraviroc (Compound) binds CYP3A4 (Gene)
Maraviroc (Compound) upregulates CNPY3 (Gene)
Maraviroc (Compound) is included by Chemokine Co-receptor 5 Antagonists (Pharmacologic Class)
Maraviroc (Compound) downregulates NPDC1 (Gene)
Maraviroc (Compound) causes Herpes virus infection (Side Effect)
Maraviroc may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil
Maraviroc may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Maraviroc may lead to a major life threatening interaction when taken with Leflunomide
Maraviroc may lead to a major life threatening interaction when taken with Idelalisib